Head of Market Access at Lxbio Pharmaceuticals, a SME dedicated to R&D on 2 technology platforms ; bacteriophage cocktails (AMR infections), Antibodies and Phage conjugates (oncology). Seeking partners for late stage porfolio (phase III)
Founded in 2021, Lxbio Pharmaceuticals is a Portuguese biopharmaceutical company dedicated to the development of next-generation biological therapies. The company operates at the intersection of bacteriophage science and antibody engineering, with a primary focus on antimicrobial resistant (AMR) infections and targeted oncology, while selectively expanding into immune-mediated diseases with high unmet medical need. Lxbio’s pipeline is anchored in two core platforms: bacteriophage-based therapeutics and antibody–phage conjugates. The latter are designed to enable substantially higher payload capacity compared to conventional antibody-drug conjugates, offering a differentiated approach for difficult-to-treat cancers, where therapeutic intensity and targeted delivery remain limiting factors. Lxbio maintains a specialized R&D capability supporting biologics discovery and early development, including antibody generation and translational strategy. This integrated model accelerates the progression of assets from preclinical validation to clinical readiness, reinforcing the company’s ability to translate scientific innovation into viable therapeutic candidates. Lxbio collaborates with academic institutions, biotechnology partners, and public-sector initiatives across Europe to advance its programs within pragmatic and scientifically robust development pathways. The company’s approach is grounded in disciplined execution and a clear objective: to deliver clinically meaningful, scalable solutions in areas where current therapeutic options remain insufficient. The company also provides antibody discovery services through its CRO arm, Lxbio AB. This part of the company specializes in advancing therapeutic and research antibody development, offering end-to-end antibody discovery, engineering and characterization services. From automated high-throughput screening to advanced cell line development, Lxbio AB leverages cutting-edge tools and methodologies to deliver scalable, high-quality antibody solutions tailored to your project. 𝐘𝐨𝐮𝐫 𝐈𝐝𝐞𝐚, 𝐘𝐨𝐮𝐫 𝐏𝐫𝐨𝐣𝐞𝐜𝐭, 𝐎𝐮𝐫 𝐌𝐢𝐬𝐬𝐢𝐨𝐧. 𝐓𝐞𝐥𝐥 𝐮𝐬 𝐰𝐡𝐚𝐭 𝐲𝐨𝐮 𝐰𝐚𝐧𝐭; 𝐰𝐞 𝐰𝐢𝐥𝐥 𝐝𝐞𝐥𝐢𝐯𝐞𝐫 𝐭𝐨 𝐲𝐨𝐮.
Luis Rocha is current Head of Market Access at Lxbio Pharmaceuticals, a biotech SME developing innovative platforms in bacteriophage, antibodies and antibody–phage conjugates. He brings over three decades of leadership experience across top-tier pharmaceutical companies, including Novartis, Pfizer, and MSD, with a strong track record in market access, health economics, public affairs, and commercial strategy. At Novartis, he served on the Portugal Executive Committee and the European Public Affairs Network. More recently, he has operated as a healthcare consultant and commercial leader in digital health, bridging biotechnology, policy, and market adoption. Luis holds an MSc in Business Administration and a postgraduate degree in Health Economics, complemented by executive education at INSEAD, Oxford Saïd, Harvard, Johns Hopkins, and Nova SBE.